| $385M | ||
| $350M | ||
| $215M | ||
| $88M | ||
| $82M | ||
| $62M |
Buys | $125,484 | 1 | 11 |
Sells | $4,770,642 | 8 | 89 |
| Opaleye Management Inc. | 10 percent owner | 1 | $125,484 | 0 | $0 | $125,484 |
| Krempa David | Chief Business Officer | 0 | $0 | 3 | $504,318 | $-504,318 |
| Gruber James R. | Chief Financial Officer | 0 | $0 | 2 | $673,714 | $-673,714 |
| BRYNJELSEN SEAN | President & CEO | 0 | $0 | 3 | $3.59M | $-3.59M |
Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical products for rare diseases. The company offers Biorphen, a phenylephrine injection for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; and Rezipres, a ready-to-use formulation of a molecule that is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia. It also offers Alkindi Sprinkle, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; EPRONTIA, a liquid formulation of topiramate; and Alaway Preservative Free, a preservative-free ophthalmic product to treat allergic conjunctivitis. In addition, the company develops Zonisamide Oral Suspension for the treatment of partial on-set seizures; Lamotrigine for Oral Suspension for the treatment of partial on-set seizures; cysteine injection; dehydrated alcohol injection; and Zeneo hydrocortisone autoinjector. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
Over the last 12 months, insiders at Eton Pharmaceuticals, Inc. have bought $125,484 and sold $4.77M worth of Eton Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at Eton Pharmaceuticals, Inc. have bought $315,125 and sold $12.77M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Opaleye Management Inc. (10 percent owner) — $125,484.
The last purchase of 7,930 shares for transaction amount of $125,484 was made by Opaleye Management Inc. (10 percent owner) on 2025‑06‑10.
| 2025-08-20 | Sale | Gruber James R. | Chief Financial Officer | 2,631 0.0095% | $16.02 | $42,149 | +2.51% | |
| 2025-08-19 | Sale | Gruber James R. | Chief Financial Officer | 39,082 0.1454% | $16.16 | $631,565 | +4.57% | |
| 2025-06-16 | Sale | Krempa David | Chief Business Officer | 10,223 0.0396% | $14.73 | $150,585 | +16.80% | |
| 2025-06-13 | Sale | Krempa David | Chief Business Officer | 6,800 0.0262% | $14.77 | $100,436 | +15.73% | |
| 2025-06-12 | Sale | Krempa David | Chief Business Officer | 16,977 0.0651% | $14.92 | $253,297 | +14.06% | |
| 2025-06-10 | Opaleye Management Inc. | 10 percent owner | 7,930 0.0298% | $15.82 | $125,484 | +5.16% | ||
| 2025-06-05 | Sale | BRYNJELSEN SEAN | President & CEO | 70,000 0.2544% | $16.81 | $1.18M | -4.26% | |
| 2025-06-04 | Sale | BRYNJELSEN SEAN | President & CEO | 70,000 0.2618% | $17.00 | $1.19M | -2.54% | |
| 2025-06-03 | Sale | BRYNJELSEN SEAN | President & CEO | 70,000 0.2645% | $17.51 | $1.23M | -4.31% | |
| 2024-10-23 | Opaleye Management Inc. | 10 percent owner | 10,000 0.0782% | $7.98 | $79,814 | +84.87% | ||
| 2024-10-08 | Opaleye Management Inc. | 10 percent owner | 33,970 0.2339% | $7.03 | $238,782 | +97.23% | ||
| 2024-10-07 | Opaleye Management Inc. | 10 percent owner | 11,248 0.0796% | $7.22 | $81,250 | +99.86% | ||
| 2024-10-04 | Opaleye Management Inc. | 10 percent owner | 16,852 0.1118% | $6.77 | $114,105 | +107.71% | ||
| 2024-09-11 | Opaleye Management Inc. | 10 percent owner | 50,000 0.2326% | $4.75 | $237,500 | +198.64% | ||
| 2024-09-10 | Opaleye Management Inc. | 10 percent owner | 57,500 0.2619% | $4.65 | $267,375 | +199.16% | ||
| 2022-09-22 | BRYNJELSEN SEAN | Chief Executive Officer | 10,000 0.0382% | $2.10 | $21,042 | +61.06% | ||
| 2021-11-17 | Sale | Opaleye Management Inc. | 10 percent owner | 25,000 0.1% | $4.67 | $116,713 | -31.32% | |
| 2021-11-16 | Sale | Opaleye Management Inc. | 10 percent owner | 12,438 0.0495% | $4.86 | $60,472 | -34.12% | |
| 2021-11-15 | Sale | Opaleye Management Inc. | 10 percent owner | 3,000 0.0112% | $4.80 | $14,405 | -37.28% | |
| 2021-11-08 | Sale | Opaleye Management Inc. | 10 percent owner | 52,661 0.2268% | $6.10 | $321,285 | -41.81% |
| BRYNJELSEN SEAN | President & CEO | 2873513 10.7151% | $49.05M | 7 | 3 | <0.0001% |
| Opaleye Management Inc. | 10 percent owner | 2770000 10.3291% | $47.28M | 8 | 17 | +111.94% |
| Krempa David | Chief Business Officer | 612646 2.2845% | $10.46M | 0 | 3 | |
| Gruber James R. | Chief Financial Officer | 204753 0.7635% | $3.5M | 0 | 2 | |
| HARROW HEALTH, INC. | 10 percent owner | 1982000 7.3907% | $33.83M | 0 | 1 | |
| CASAMENTO CHARLES J | director | 71920 0.2682% | $1.23M | 2 | 0 | +1.97% |
| RIEDEL NORBERT G | director | 59745 0.2228% | $1.02M | 1 | 0 | +7.11% |
| MAIER PAUL V | director | 59745 0.2228% | $1.02M | 1 | 0 | +7.11% |
| Troutman William Wilson | CFO, Treasurer & Secretary | 23027 0.0859% | $393,070.89 | 2 | 0 | <0.0001% |
| BAUM MARK L | director | 10000 0.0373% | $170,700.00 | 1 | 0 | +7.11% |
$17,468,215 | 46 | 18.85% | $444.22M | |
$24,384,691 | 42 | -30.27% | $399.81M | |
$74,231,875 | 30 | 40.62% | $415.83M | |
Eton Pharmaceuticals, Inc. (ETON) | $4,306,464 | 21 | 37.34% | $457.78M |
$112,238,340 | 19 | 39.16% | $482.32M | |
$2,516,932 | 19 | -15.78% | $461.52M | |
$8,069,667 | 13 | -13.57% | $500.69M | |
$57,263,116 | 11 | -8.37% | $404.51M | |
$603,645 | 8 | 57.40% | $402.24M | |
$166,385 | 7 | -23.62% | $452.24M | |
$43,326,461 | 6 | 16.01% | $442.74M | |
$79,246,559 | 5 | -27.73% | $482.26M | |
$88,549,962 | 5 | -16.91% | $476.92M | |
$4,745,999 | 5 | -4.91% | $395.34M | |
$144,224 | 4 | 21.31% | $478.53M | |
$58,352 | 4 | -43.78% | $499.96M | |
$10,104,842 | 3 | 5.45% | $460.55M | |
$2,857,000 | 2 | -5.23% | $494.27M | |
$3,850,000 | 1 | -51.32% | $404.48M |
| Increased Positions | 52 | +44.07% | 2M | +12.83% |
| Decreased Positions | 50 | -42.37% | 2M | -9.05% |
| New Positions | 25 | New | 567,590 | New |
| Sold Out Positions | 16 | Sold Out | 390,882 | Sold Out |
| Total Postitions | 120 | +1.69% | 18M | +3.78% |
| Opaleye Management Inc. | $46,504.00 | 10.59% | 2.86M | 0 | 0% | 2025-09-30 |
| Ecor1 Capital, Llc | $33,017.00 | 7.52% | 2.03M | 0 | 0% | 2025-09-30 |
| Blackrock, Inc. | $27,713.00 | 6.31% | 1.7M | +172,650 | +11.27% | 2025-09-30 |
| Vanguard Group Inc | $21,855.00 | 4.98% | 1.34M | +31,942 | +2.43% | 2025-09-30 |
| Nantahala Capital Management, Llc | $19,121.00 | 4.36% | 1.18M | 0 | 0% | 2025-09-30 |
| Morgan Stanley | $9,529.00 | 2.17% | 586,046 | +76,478 | +15.01% | 2025-09-30 |
| Geode Capital Management, Llc | $9,334.00 | 2.13% | 574,030 | -18,835 | -3.18% | 2025-09-30 |
| Royal Bank Of Canada | $7,792.00 | 1.78% | 479,193 | +474,128 | +9,360.87% | 2025-09-30 |
| Westside Investment Management, Inc. | $7,684.00 | 1.75% | 472,540 | -250 | -0.05% | 2025-09-30 |
| Cannell Capital Llc | $7,405.00 | 1.69% | 455,405 | +67,230 | +17.32% | 2025-09-30 |